{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:52:16Z","timestamp":1786737136343,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/ijd.ijd_194_19","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T06:44:28Z","timestamp":1597041868000},"page":"396","source":"Crossref","is-referenced-by-count":3,"title":["Real-world insight on apremilast therapy in patients with plaque psoriasis: Indian experience"],"prefix":"10.4103","volume":"65","author":[{"given":"Dhiraj","family":"Dhoot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudip","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Sarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-5154.291793-1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4103\/2229-5178.193906","article-title":"Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring","author":"Dogra","year":"2016","journal-title":"Indian Dermatol Online J","ISSN":"https:\/\/id.crossref.org\/issn\/2229-5178","issn-type":"print"},{"key":"key-10.4103\/0019-5154.291793-2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1.Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0019-5154.291793-3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2.Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics","author":"Gottlieb","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0019-5154.291793-4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.clindermatol.2007.08.007","article-title":"Psoriasis: Epidemiology","author":"Gudjonsson","year":"2007","journal-title":"Clin Dermatol"},{"key":"key-10.4103\/0019-5154.291793-5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jdv.12163","article-title":"Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: A systematic literature review","author":"Horreau","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0019-5154.291793-6","doi-asserted-by":"crossref","unstructured":"Puig L, Kirby B, Mallbris L, Strohal R. Psoriasis beyond the skin: A review of the literature on cardiometabolic and psychological co-morbidities of psoriasis. Eur J Dermatol 2014;24:305-11.","DOI":"10.1684\/ejd.2014.2299"},{"key":"key-10.4103\/0019-5154.291793-7","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","author":"Schafer","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"key-10.4103\/0019-5154.291793-8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cellsig.2016.01.007","article-title":"Phosphodiesterase 4 in inflammatory diseases: Effects of Apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4\/CD271 complex","author":"Schafer","year":"2016","journal-title":"Cell Signal"},{"key":"key-10.4103\/0019-5154.291793-9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: Results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey","author":"Lebwohl","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0019-5154.291793-10","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40265-015-0439-1","article-title":"Apremilast: A review in psoriasis and psoriatic arthritis","author":"Deeks","year":"2015","journal-title":"Drugs"},{"key":"key-10.4103\/0019-5154.291793-11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40259-015-0144-3","article-title":"Selective phosphodiesterase inhibitors for psoriasis: Focus on apremilast","author":"Gooderham","year":"2015","journal-title":"BioDrugs"},{"key":"key-10.4103\/0019-5154.291793-12","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/jdv.14832","article-title":"Real-world data on the efficacy and safety of Apremilast in patients with moderate-to-severe plaque psoriasis","author":"Papadavid","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0019-5154.291793-13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/1346-8138.14617","article-title":"Real-world use of apremilast for patients with psoriasis in Japan","author":"Kishimoto","year":"2018","journal-title":"J Dermatol"},{"key":"key-10.4103\/0019-5154.291793-14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0019-5154.291793-15","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: A phase III, randomised controlled trial (ESTEEM 2)","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0019-5154.291793-16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of Apremilast, Etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomised, placebo-controlled trial (LIBERATE)","author":"Reich","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0019-5154.291793-17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial","author":"Papp","year":"2012","journal-title":"Lancet"},{"key":"key-10.4103\/0019-5154.291793-18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1203475416676030","article-title":"Real-world experience with apremilast in treating psoriasis","author":"Mayba","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"key-10.4103\/0019-5154.291793-19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/ced.13150","article-title":"Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis","author":"Wong","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"key-10.4103\/0019-5154.291793-20","unstructured":"Reich K, Bomas S, Korge B, Manasterski M, Schwichtenberg U, Altmann M, et al. First \u201creal-world\u201d insights on Apremilast therapy for patients with plaque psoriasis from the LAPIS-PSO study: An interim analysis. Available from: https:\/\/www.aad.org\/eposters\/submissions\/getFile.aspx?id=5137&type= sub. [Last accessed on 2019 Apr 04]."},{"key":"key-10.4103\/0019-5154.291793-21","first-page":"1","article-title":"Psoriasis management; patient feedback and healthcare limitations","author":"Aldeen","year":"2016","journal-title":"Clin Dermatol Res J"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:50:36Z","timestamp":1786733436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.IJD_194_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"alternative-id":["291793"],"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_194_19","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}